Insulin resistance is associated with increased circulating level of thrombin-activatable fibrinolysis inhibitor in type 2 diabetic patients

Journal of Clinical Endocrinology and Metabolism

Volumn 87, Issue 2, 2002, Pages 660-665

  Hori, Yasuko ^a   Gabazza, Esteban C ^a,b   Yano, Yukata ^a   Katsuki, Akira ^b   Suzuki, Koji ^a   Adachi, Yukihiko ^a   Sumida, Yasuhiro ^a  

^a MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b MIE UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR;

ADIPOSE TISSUE; ADULT; ARTICLE; BLOOD LEVEL; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORRELATION FUNCTION; DISEASE ASSOCIATION; ENDOTHELIUM CELL; FEMALE; FIBRINOLYSIS; GLUCOSE INFUSION; GLUCOSE INTOLERANCE; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PLASMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR;

EID: 0036172375     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jcem.87.2.8214     Document Type: Article

References (29)

1. Haemostatic variables associated with diabetes and its complications
2. Diabetes, fibrinogen, and risk of cardiovascular disease: The Framingham experience
3. Effect of diabetes on the coagulation and fibrinolytic systems and its implications for atherogenesis
4. Hemotatic function and coronary artery disease
5. Acute myocardial infarction: A failure of timely, spontaneous thrombolysis
6. Plasminogen activator inhibitor activity in diabetic and nondiabetic survivors of myocardial infarction
7. Abnormal endothelial release of fibrinolytic activity and fibronectin in diabetic microangiopathy
8. Increased plasma levelsn of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction
9. Attenuated fibrinolysis and accelerated atherogenesis in type II diabetes patients
10. Risk variable clustering in the insulin resistance syndrome
11. Insulin resistance
12. Carboxypeptidase U, a plasma carboxypeptidase with high affinity for plasminogen
13. Purification and characterization of TAFI, a thrombin-activatable fibrinolysis inhibitor
14. Protein C activation in NIDDM patients
15. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation
16. Analysis of serum lipid levels in Japanese men and women according to body mass index. Increase in risk of atherosclerosis in postmenopausal women
17. Risk factor analysis for macrovascular complication in non-obese NIDDM patients
18. A novel technique for the determination of body fat by computed tomography
19. Glucose clamp technique: A method for quantifying insulin secretion and resistance
20. Activation of trombim-activable fibrinolysis inhibitor requires epidermal growth factor-like domain 3 of thrombomodulin and is inhibited competitively by protein C
21. Obesity as a medical problem
22. Characterization of mouse thrombin-activatable fibrinolysis inhibitor
23. The regulation of natural anticoagulant pathways
24. Both cellular and soluble forms of thrombomodulin inhibit fibrinolysis by potentiating the activation of thrombin-activatable fibrinolysis inhibitor
25. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex
26. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activatable fibrinolysis inhibitor
27. Regulation of fibrinolysis in the development of atherothrombosis: Role of adipose tissue
28. Hemostatic gene expression and vascular disease in obesity: Insights from studies of genetically obese mice
29. PAI-1, obesity, insulin resistance and risk of cardiovascular events